Controversies and challenges in HLA-haplotype-matched transplants for leukaemia.

abstract：:Successful allogeneic hematopoietic transplants require conditioning regimens with sufficient immunosuppression to allow acceptance of the allograft. Cyclophosphamide, in combination either with TBI or with chemotherapeutic drugs, is the keystone of commonly used regimens. The toxicities of TBI and tumor resistance to...

journal_title：Bone marrow transplantation

authors： Oblon DJ,Paul S,Yankee R

更新日期：1997-09-01 00:00:00

abstract：:Thirty patients with relapsed pediatric solid tumors received high-dose carboplatin and etoposide with autologous marrow support in a dose-escalation trial. These patients had received extensive prior treatment, which included both cisplatin and etoposide in 25 cases. Six patient cohorts received carboplatin in doses ...

journal_title：Bone marrow transplantation

authors： Santana VM,Schell MJ,Williams R,Bowman LC,Thompson EI,Brenner MK,Mirro J Jr

更新日期：1992-11-01 00:00:00

abstract：:Very long delay to engraftment (or non-engraftment) was observed in eight patients presenting common immunological features, i.e. excess of blood and bone marrow lymphocytes coexpressing CD8 and CD57 (HNK1) antigens. They were therefore treated by CD8 immunotherapy. Such treatment induced a complete clearance of CD8+,...

journal_title：Bone marrow transplantation

authors： Favrot M,Philip T,Combaret V,Lemerle J,Marie JP,Bernard A

更新日期：1990-01-01 00:00:00

abstract：:Over the past 15 years, SCT has emerged as a promising treatment option for patients with severe autoimmune diseases (ADs). Mechanistic studies recently provided the proof-of-concept that restoration of immunological tolerance can be achieved by haematopoietic SCT in chronic autoimmunity through eradication of the pat...

journal_title：Bone marrow transplantation

authors： Alexander T,Bondanza A,Muraro PA,Greco R,Saccardi R,Daikeler T,Kazmi M,Hawkey C,Simoes BP,Leblanc K,Fibbe WE,Moore J,Snarski E,Martin T,Hiepe F,Velardi A,Toubert A,Snowden JA,Farge D

更新日期：2015-02-01 00:00:00

abstract：:Nine normal bone marrow donors aged 7-166 months (median 69 months) received autologous red cells which had been removed from their marrow harvest after collection. The median volume of marrow removed from the donors was 18.6 ml/kg which was equivalent to a median blood volume loss of 23.3%. Three infant donors were t...

journal_title：Bone marrow transplantation

authors： Chan KW,Herd SL,Stanley CE,Wadsworth LD

更新日期：1992-05-01 00:00:00

abstract：:This study was performed to investigate the therapeutic effect of umbilical cord serum eyedrops on dry eye associated with graft-versus-host disease (GVHD). Twenty-four eyes of 12 patients with severe dry eye syndrome associated with GVHD were treated with 20% umbilical cord serum eyedrops. Symptom scoring, corneal se...

journal_title：Bone marrow transplantation

authors： Yoon KC,Jeong IY,Im SK,Park YG,Kim HJ,Choi J

更新日期：2007-02-01 00:00:00

abstract：:Congenital erythropoietic porphyria (Gunther's disease, GD) is a rare autosomal recessive disease. It results from the deficiency of uroporphyrinogen III synthase, the fourth enzyme on the metabolic pathway of heme synthesis. GD leads to severe scarring of the face and hands as a result of photosensitivity and fragili...

journal_title：Bone marrow transplantation

authors： Zix-Kieffer I,Langer B,Eyer D,Acar G,Racadot E,Schlaeder G,Oberlin F,Lutz P

更新日期：1996-07-01 00:00:00

abstract：:The Janus-activated kinase 1 (JAK1) and JAK2 inhibitor ruxolitinib is effective in decreasing symptomatic splenomegaly and myelofibrosis (MF)-related symptoms. However, allogeneic hematopoietic cell transplantation (HCT) remains the only curative option. We evaluated the impact of ruxolitinib on the outcome after HCT....

journal_title：Bone marrow transplantation

authors： Jaekel N,Behre G,Behning A,Wickenhauser C,Lange T,Niederwieser D,Al-Ali HK

更新日期：2014-02-01 00:00:00

abstract：:Relapse rates in patients after autologous bone marrow transplantation (BMT) for acute myeloid leukemia (AML) continue to be high despite the use of aggressive conditioning regimens. Based on studies in the murine system a clinical protocol was developed that utilizes immunotherapy to obtain a graft-versus-leukemia (G...

journal_title：Bone marrow transplantation

authors： Klingemann HG,Eaves CJ,Barnett MJ,Eaves AC,Hogge DE,Nantel SH,Reece E,Shepherd JD,Sutherland HJ,Phillips GL

更新日期：1994-09-01 00:00:00

abstract：:This study was designed to test the efficacy and toxicity of combining high-dose cytarabine (3 g/m2 every 12 h x 8 doses day -7 to day -4, total dose 24 g/m2), methyl prednisolone (0.5 mg/kg every 4 h day -7 to day -1), and cyclophosphamide (CY) (60 mg/kg day -3 and day -2) with either total body irradiation (TBI) (90...

journal_title：Bone marrow transplantation

authors： Broun ER,Tricot G,Akard L,Nichols C,Cheerva A,Jansen J

更新日期：1990-05-01 00:00:00

abstract：:Conditioning regimens preceding hematopoietic SCT (HSCT) usually consist of high-dose chemotherapy. Chemotherapy and radiation therapy are associated with increased formation of free radicals and depletion of critical plasma and tissue antioxidants. Oxidative stress and antioxidant depletion have been described during...

journal_title：Bone marrow transplantation

authors： Sabuncuoğlu S,Kuşkonmaz B,Uckun Çetinkaya D,Ozgüneş H

更新日期：2012-05-01 00:00:00

abstract：:Clostridium difficile is the most common cause of nosocomial diarrhea in the United States and Europe, and is a cause of significant morbidity and mortality among hospitalized patients. A newly identified epidemic strain has been associated with many hospital outbreaks of C. difficile-associated disease (CDAD), raisin...

journal_title：Bone marrow transplantation

authors： Bobak D,Arfons LM,Creger RJ,Lazarus HM

更新日期：2008-12-01 00:00:00

abstract：:Cyclosporin A (CsA) has been used clinically to induce graft-versus-host disease following autologous bone marrow transplantation in an attempt to destroy residual leukemia cells and reduce relapse. To analyze the antitumor potential of murine syngeneic graft-versus-host disease (SGVHD), C3H/HeN mice were lethally irr...

journal_title：Bone marrow transplantation

authors： Bryson JS,Jennings CD,Lowery DM,Carlson SL,Pflugh DL,Caywood BE,Kaplan AM

更新日期：1999-02-01 00:00:00

abstract：:A series of 22 consecutive pediatric patients undergoing ABMT for treatment of primary AML was reviewed in an efficacy analysis of recombinant human granulocytemacrophage colony-stimulating factor (rhGM-CSF). Treatment with at least two cycles of chemotherapy and a standard conditioning regimen of busulfan and cycloph...

journal_title：Bone marrow transplantation

authors： Calderwood S,Doyle JJ,Hitzler JK,Saunders EF,Freedman MH

更新日期：1996-07-01 00:00:00

abstract：:Intermediate-dose salvage therapy is frequently given for relapsed and resistant lymphomas and is usually intensely myelosuppressive. In an attempt to reduce the haematological toxicity of miniBEAM, one of the commonly used salvage regimens, peripheral blood stem cell (PBSC) support was given to 21 consecutive patient...

journal_title：Bone marrow transplantation

authors： Fielding AK,Goldstone AH,Sullivan AM,Watts MJ,Jamieson E,Linch DC

更新日期：1996-09-01 00:00:00

abstract：:Progressive multifocal leukoencephalopathy (PML) is a rare subacute demyelinating disorder of the central nervous system (CNS) caused by the DNA JC human polyomavirus. In immunocompromised hosts, PML is caused by reactivation of a latent infection rather than de novo primary exposure. PML in the setting of hematopoiet...

journal_title：Bone marrow transplantation

authors： Kharfan-Dabaja MA,Ayala E,Greene J,Rojiani A,Murtagh FR,Anasetti C

更新日期：2007-01-01 00:00:00

abstract：:A 42-year-old male underwent an HLA-matched sibling PBSC transplant for hypereosinophilic syndrome (HES) diagnosed in August 1995. Prior to transplant he experienced progressive cardiac and pulmonary dysfunction with red cell and platelet transfusion dependence despite therapy with hydroxyurea, steroids and interferon...

journal_title：Bone marrow transplantation

authors： Chockalingam A,Jalil A,Shadduck RK,Lister J

更新日期：1999-05-01 00:00:00

abstract：:A retrospective comparison was carried out on adult patients receiving HLA-identical allogeneic haemopoietic stem cell transplants from siblings in Australia in 1996, comparing bone marrow with G-CSF-mobilised peripheral blood stem cells. A total of 131 transplant recipients from nine centres were included in this stu...

journal_title：Bone marrow transplantation

authors： Nivison-Smith I,Bradstock KF,Szer J,Durrant S,Dodds A,Hermann R,Schwarer AP,Gibson J,To LB,Arthur C,Australian Bone Marrow Transplant Cooperative Sutdy Group.

更新日期：2001-07-01 00:00:00

abstract：:Still, many physicians give 4 cycles of combination therapy to multiple myeloma patients prior to collection of stem cells for autologous bone marrow transplant. This tradition originates from older doxorubicin-containing regiments which limited the number of cycles due to cumulative cardiotoxicity. Using older regime...

journal_title：Bone marrow transplantation

authors： Tageja N,Korde N,Kazandjian D,Panch S,Manasanch E,Bhutani M,Kwok M,Mailankody S,Yuan C,Stetler-Stevenson M,Leitman SF,Sportes C,Landgren O

更新日期：2018-11-01 00:00:00

abstract：:A 20-month-old boy with infantile leukemia was treated with total body irradiation, etoposide, cyclophosphamide and unrelated cord blood transplantation with a one-antigen mismatch. He relapsed on day 100 and achieved remission after ubenimex administration, and also developed chronic graft-versus-host disease of the ...

journal_title：Bone marrow transplantation

authors： Okada H,Nomi K,Hamatani S,Kuromi T,Nanba M,Imai T,Isobe K,Itoh S

更新日期：2002-10-01 00:00:00

abstract：:Quality of life (QOL) is increasingly recognized as an important clinical outcome of hematopoietic cell transplantation (HCT), but patient education is often overlooked. The aim of the current qualitative study was to examine education regarding post-HCT QOL from the patient's perspective. Allogeneic HCT recipients pa...

journal_title：Bone marrow transplantation

authors： Jim HS,Quinn GP,Gwede CK,Cases MG,Barata A,Cessna J,Christie J,Gonzalez L,Koskan A,Pidala J

更新日期：2014-02-01 00:00:00

abstract：:We previously reported a 25% incidence of serious graft-versus-host disease (GVHD) (that is, acute or chronic GVHD that caused death, lengthy hospitalization or disability, or resulted in recurrent major infections) among 171 hematopoietic cell transplantation (HCT) recipients after nonmyeloablative (NMA) regimen. Her...

journal_title：Bone marrow transplantation

authors： Sala-Torra O,Martin PJ,Storer B,Traina F,Sorror ML,Storb R,Sandmaier BM,Flowers ME

更新日期：2008-05-01 00:00:00

abstract：:Primitive haemopoietic cells are required for studies in both the clinical and research fields and a number of systems have been developed to facilitate isolation of these haemopoietic cell populations. We have analysed the results from several European centres using positive selection of CD34+ cells from haemopoietic...

journal_title：Bone marrow transplantation

authors： de Wynter EA,Ryder D,Lanza F,Nadali G,Johnsen H,Denning-Kendall P,Thing-Mortensen B,Silvestri F,Testa NG

更新日期：1999-06-01 00:00:00

abstract：:An unblinded, historical controlled study of 49 bone marrow transplant (BMT) patients was carried out in our institution to assess the effect of oral pentoxifylline (PTX) on BMT regimen related toxicity (RRT). Twenty-eight consecutively treated BMT patients (17 allogeneic, 11 autologous) were entered into the PTX trea...

journal_title：Bone marrow transplantation

authors： van der Jagt RH,Pari G,McDiarmid SA,Boisvert DM,Huebsch LB

更新日期：1994-02-01 00:00:00

abstract：:HLA-identical sibling donor transplantation remains the treatment of choice for Wiskott-Aldrich Syndrome (WAS). Since 1990, utilization of alternative donor sources has increased significantly. We report the hematopoietic cell transplantation (HCT) outcomes of 47 patients with WAS treated at a single center since 1990...

journal_title：Bone marrow transplantation

authors： Shin CR,Kim MO,Li D,Bleesing JJ,Harris R,Mehta P,Jodele S,Jordan MB,Marsh RA,Davies SM,Filipovich AH

更新日期：2012-11-01 00:00:00

abstract：:Blood concentrations of cyclosporine A (CsA) >or=800 microg/l measured 2 h post-dosing, the C2 concentration, is necessary to obtain a maximal pharmacological effect and correlates well with transplant-related complications such as transplant rejection and toxicity. In an open crossover study CsA blood levels were mea...

journal_title：Bone marrow transplantation

authors： Hendriks MP,Blijlevens NM,Schattenberg AV,Burger DM,Donnelly JP

更新日期：2006-10-01 00:00:00

abstract：:Data from human clinical trials and animal experiments have suggested that T lymphocytes in donor marrow help to facilitate engraftment after allogeneic bone marrow transplantation, possibly through a suppressive effect on the immunity of the recipient. In previous studies marrows from HLA-identical donors were treate...

journal_title：Bone marrow transplantation

authors： Martin PJ,Hansen JA,Torok-Storb B,Moretti L,Press O,Storb R,Thomas ED,Weiden PL,Vitetta ES

更新日期：1988-09-01 00:00:00

abstract：:Extracorporeal photopheresis (ECP) is beneficial in patients with T-cell-mediated disorders, including GvHD, but the underlying immunological mechanisms are incompletely understood. Myeloid-derived suppressor cells (MDSCs) are innate immune cells characterized by their capacity to suppress T-cell proliferation. We qua...

journal_title：Bone marrow transplantation

authors： Rieber N,Wecker I,Neri D,Fuchs K,Schäfer I,Brand A,Pfeiffer M,Lang P,Bethge W,Amon O,Handgretinger R,Hartl D

更新日期：2014-04-01 00:00:00

abstract：:Autologous hematopoietic stem cell transplantation (HSCT) is currently being evaluated as a therapy for patients with progressive multiple sclerosis (MS) at risk of debilitating neurological impairment. While preliminary results from a few studies have been reported, little is known about toxicities or outcome of HSCT...

journal_title：Bone marrow transplantation

authors： Oyama Y,Cohen B,Traynor A,Brush M,Rodriguez J,Burt RK

更新日期：2002-01-01 00:00:00

abstract：:Corticosteroid-resistant GVHD is difficult to manage and is associated with high morbidity and mortality. Cyclophosphamide (Cy) is an established immunosuppressive and cytotoxic drug widely used as part of pretransplant conditioning regimens. In a retrospective study of 15 patients who had not responded to corticoster...

journal_title：Bone marrow transplantation

authors： Mayer J,Krejcí M,Doubek M,Pospísil Z,Brychtová Y,Tomíska M,Rácil Z

更新日期：2005-04-01 00:00:00